TIME BioVentures

Phantom Neuro specializes in developing innovative muscle-machine interfaces that enhance robotic limb rehabilitation. The company focuses on creating solutions that improve mobility for users by integrating neurotechnology with robotic systems, aiming to facilitate precise control of robotic limbs and enable more natural movement.

Conceivable Life Sciences is developing an AI-powered automated IVF lab to increase accessibility to in vitro fertilization.

Rivermark Medical is a medical device company focused on developing minimally invasive therapies for Benign Prostatic Hyperplasia (BPH), a condition that significantly impacts urinary function. The technology, created by urologists, aims to provide effective symptom relief while minimizing side effects and patient downtime. This innovative treatment allows for a swift return to normal daily activities, eliminating the need for post-procedural catheters and ensuring a reliable reduction in BPH symptoms. Rivermark Medical’s approach reflects a commitment to improving patient outcomes through advanced medical solutions.

Brightside Health is a telemedicine platform focused on mental health treatment for anxiety and depression. It delivers evidence-based care through video visits, messaging, ongoing support, and medication delivery, backed by a network of providers who conduct depression evaluation, treatment, and monitoring. The platform combines precision psychiatry with clinically proven therapy and continuous care monitoring to help patients achieve and maintain improvement. It supports communication, scheduling, and access to information about health and wellness related to depression, and tracks progress throughout treatment. Founded in 2017 and based in San Francisco.

Commons Clinic is a multispecialty healthcare provider based in Austin, Texas, founded in 2021. It delivers comprehensive specialty and surgical care for pain, orthopedics, women's health, and men's health. The company also develops a healthcare platform that combines preventive diagnostics with specialist-driven interventions, uniting advanced diagnostics, personalized care pathways, and interventional procedures within an accountable system across musculoskeletal care, women's health, and preventive oncology to support informed clinical decisions and improved patient outcomes.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

Phantom Neuro specializes in developing innovative muscle-machine interfaces that enhance robotic limb rehabilitation. The company focuses on creating solutions that improve mobility for users by integrating neurotechnology with robotic systems, aiming to facilitate precise control of robotic limbs and enable more natural movement.

BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.

NanoMosaic is a biotechnology company focused on advancing early illness detection, prognostic monitoring, and biomarker identification through its innovative nanoneedle technology. The company's proprietary proteomic platform utilizes nanoneedles to enable precise protein detection and quantification. By integrating these capabilities onto a single chip, NanoMosaic aims to enhance the efficiency and accuracy of biomarker discovery and validation processes. This technology is designed to support the medical and healthcare industries in improving diagnostic capabilities and patient outcomes.

DeepSight Technology enhances diagnostic medical imaging by advancing ultrasound technology. It offers proprietary sensing technology and customizable systems, integrating with industry partners to provide clinicians with deeper insights for improved patient outcomes.